September 4, 2025 — Leads & Copy — Tharimmune, Inc. (Nasdaq: THAR) will participate in three upcoming Fall conferences. The clinical-stage biotechnology company develops therapeutic candidates for inflammation, immunology, and critical unmet medical needs.
The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Center in Phoenix, AZ; and the American Association for the Study of Liver Diseases (AASLD) Annual Conference, The Liver Meeting® 2025 to be held November 7 -10, 2025, in Washington, DC; as well as the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 to be held November 9-12, 2025, in San Antonio, Texas.
Event:ACG 2024 Annual Scientific Meeting
Date:Sunday, October 26, 2025
Time:3:30 p.m. – 4:30 p.m. Pacific Time
Location:Exhibit Hall, Phoenix Convention Center
Event:The Liver Meeting® 2025 Annual Scientific Meeting
Date:Monday, November 10, 2025
Time:1:00 p.m. – 2:00 p.m. Eastern Time
Location:Exhibit Hall, Washington Convention Center
Event:AAPS PharmSci 360 2025 Annual Scientific Meeting
Date:November 9 – 12, 2025
Session:Late Breaker Poster Session Event
Location:Henry B. Gonzalez Convention Center, San Antonio, TX
Tharimmune is developing a portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids.
The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology.
The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders.
Contact:
ir@tharimmune.com
Source: Tharimmune, Inc.
